Application note: The need for rapid methods in the compounding pharmaceutical industry
This application note explores rapid microbial methods and balancing patient care, quality products, and safe shelf lives for unique formulations.
List view / Grid view
This application note explores rapid microbial methods and balancing patient care, quality products, and safe shelf lives for unique formulations.
European Pharmaceutical Review Issue 5 includes articles on bioprocessing, biologics, sustainability, and drug formulation.
With a growing pipeline of biologics, increase in vaccine production, and small batch sizes targeting small patient populations, there’s increasing demand for advanced manufacturing tech.
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
This bioproduction investment in Lyon, France supports Sanofi in its goals to lead in the immunology sector.
The acquisition is set to strengthen BioNTech’s capabilities in development and manufacture of next-generation bispecific antibodies.
This investment supports AstraZeneca’s strategy to drive the biopharma company's development in the US.
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
31 October 2024 | By NSF
Whitepaper - Optimising organisational culture and quality maturity is crucial in promoting consistent, reliable business processes and to minimise supply disruptions.
The new regulation could become lawful in the UK next year, according to the Medicines and Healthcare products Regulatory Agency (MHRA).
The funding aims to reduce the costs of AAV production for gene therapies, helping to accelerate treatment access for patients with rare diseases.
Gill Lewis, QP and Chief GMP Consultant, eXmoor Pharma. discusses the company's approach to environmental monitoring and the key challenges faced during integration at its Cell and Gene Therapy Centre in Bristol, a facility which received a GMP license from the MHRA in August.
The new appointee will create AI and machine learning solutions to support Eli Lilly’s medicines for patients globally.